SHARES in Omega Diagnostics closed more than 4 per cent higher yesterday after the company announced a further addition to its Covid testing armoury.

The Scottish diagnostics specialist has CE marked Mologic’s lateral flow antigen test for Covid-19, which determines whether a person is currently infected with the virus. CE is an administrative marking that indicates compliance with health and safety standards in the European Economic Area, and is required before a product can be sold.

READ MORE: Omega to receive up to £374m from UK test deal

Omega said it is now “well on the way” to establishing lateral flow test production capability of approximately two million tests per week by the end of April, by which time the Mologic antigen test will be available under Omega’s Visitect brand for use by medical professionals.

“This is an exciting and important next step in our Covid strategy as we now have the ability to supply both antigen and antibody lateral flow tests not only to the UK Government but also to our commercial partners,” chief executive Colin King said.

READ MORE: Omega signs first customer for its new Covid-19 laboratory testing service

“Having both tests available and having built our production capacity allows us to adjust our capacity to meet the demands of the pandemic.”

Production facilities at Omega’s headquarters in Alva, Clackmannanshire, will be used to fulfil demand across a range of lateral flow tests. These include: commitments to provide Covid tests under contract to the UK Government; commitments as part of the UK’s Rapid Test Consortium (UK-RTC); Visitect-branded Covid tests; and Visitect CD4 tests for the treatment of patients living with HIV.

Shares in Omega Diagnostics closed yesterday’s trading 4p higher at 92p